Biomedical Engineering Reference
In-Depth Information
65. Oudejans JJ, Slebos RJ, Zoetmulder FA,
Differential activation of
ras genes by point mutation in human colon cancer with metastases to
either lung or liver.
et al.
1991; 49: 875-879.
66. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal
carcinomas: relation to aneuploidy and metastasis.
Int J Cancer
Int J Cancer
1992;
52: 30-33.
67. Tortola S, Steinert R, Hantschick M,
Discordance between K-ras
mutations in bone marrow micrometastases and the primary tumor in
colorectal cancer.
et al.
2001; 19: 2837-2843.
68. Artale S, Sartore-Bianchi A, Veronese SM,
J Clin Oncol
Mutations of KRAS and
BRAF in primary and matched metastatic sites of colorectal cancer.
et al.
J
2008; 26: 4217-4219. doi:10.1200/JCO.2008.18.7286.
69. Loupakis F, Pollina L, Stasi I,
Clin Oncol
PTEN expression and KRAS mutations
on primary tumors and metastases in the prediction of benefit from
cetuximab plus irinotecan for patients with metastatic colorectal
cancer.
et al.
2009; 27: 2622-2629. Published on 20090427.
doi:10.1200/JCO.2008.20.2796.
70. Ahnen DJ, Feigl P, Quan G,
J Clin Oncol
Ki-ras mutation and p53 overexpression
predict the clinical behavior of colorectal cancer: a Southwest Oncology
Group study.
et al.
1998; 58: 1149-1158.
71. Andreyev HJ, Norman AR, Cunningham D,
Cancer Res
Kirsten ras mutations
in patients with colorectal cancer: the 'RASCAL II' study.
et al.
Br J Cancer
2001; 85: 692-696. doi:10.1054/bjoc.2001.1964.
72. Belly RT, Rosenblatt JD, Steinmann M,
Detection of mutated K12-
ras in histologically negative lymph nodes as an indicator of poor
prognosis in stage II colorectal cancer.
et al.
Clin Colorectal Cancer
2001; 1:
110-116.
73. Ogino S, Meyerhardt JA, Irahara N,
KRAS mutation in stage III
colon cancer and clinical outcome following intergroup trial CALGB
89803.
et al.
2009; 15: 7322-7329. Published on 20091124.
doi:10.1158/1078-0432.CCR-09-1570.
74. Roth AD, Tejpar S, Delorenzi M,
Clin Cancer Res
Prognostic role of KRAS and BRAF
in stage II and III resected colon cancer: results of the translational
study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
et al.
J Clin
2010; 28: 466-474. Published on 20091214. doi:10.1200/
JCO.2009.23.3452.
75. Karapetis CS, Khambata-Ford S, Jonker DJ,
Oncol
K-ras mutations and
benefit from cetuximab in advanced colorectal cancer.
et al.
N Engl J Med
2008; 359: 1757-1765. doi:10.1056/NEJMoa0804385.
